Modular Medical (MODD) 10-K 26 Jun 23 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2023	Jun. 22, 2023	Sep. 30, 2022
Document Information Line Items
Entity Registrant Name	Modular Medical, Inc.
Trading Symbol	MODD
Document Type	10-K
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding		21,088,823
Entity Public Float			$ 22,757,170
Amendment Flag	false
Entity Central Index Key	0001074871
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-41277
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	87-0620495
Entity Address, Address Line One	10470 Thornmint Road
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92127
City Area Code	(858)
Local Phone Number	800-3500
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Auditor Name	Farber Hass Hurley LLP
Auditor Firm ID	223
Auditor Location	Chatsworth, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Mar. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 3,799,324	$ 9,076,372
Prepaid expenses and other	146,866	313,422
Security deposit	100,000
TOTAL CURRENT ASSETS	4,046,190	9,389,794
Property and equipment, net	1,721,311	235,959
Right of use assets, net	1,477,747	120,693
Security deposit		100,000
TOTAL NON-CURRENT ASSETS	3,199,058	456,652
TOTAL ASSETS	7,245,248	9,846,446
CURRENT LIABILITIES
Accounts payable	285,383	299,951
Accrued expenses	338,698	524,891
Short-term lease liabilities	355,224	144,857
TOTAL CURRENT LIABILITIES	979,305	969,699
Long-term lease liabilities	1,189,967	39,957
TOTAL LIABILITIES	2,169,272	1,009,656
Commitments and Contingencies (Note 11)
STOCKHOLDERS’ EQUITY
Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common Stock, $0.001 par value, 50,000,000 shares authorized, 10,949,389 shares and 10,461,898 shares issued and outstanding as of March 31, 2023 and 2022, respectively	10,949	10,462
Additional paid-in capital	53,523,734	43,406,099
Accumulated deficit	(48,458,707)	(34,579,771)
TOTAL STOCKHOLDERS’ EQUITY	5,075,976	8,836,790
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 7,245,248	$ 9,846,446

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Mar. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	10,949,389	10,461,898
Common stock, shares, outstanding	10,949,389	10,461,898

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses
Research and development	$ 9,061,744	$ 7,729,240
General and administrative	4,816,567	7,197,162
Total operating expenses	13,878,311	14,926,402
Loss from operations	(13,878,311)	(14,926,402)
Other income	975	368,920
Interest expense		(2,752,229)
Loss on debt extinguishment		(1,321,450)
Loss before income taxes	(13,877,336)	(18,631,161)
Provision for income taxes	1,600	1,600
Net loss	$ (13,878,936)	$ (18,632,761)
Net loss per share
Basic net loss per share (in Dollars per share)	$ (1.28)	$ (2.74)
Shares used in computing net loss per share
Basic shares used in computing net loss per share (in Shares)	10,880,527	6,807,710

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parentheticals) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Diluted net loss per share	$ (1.28)	$ (2.74)
Diluted shares used in computing net loss per share	10,880,527	6,807,710

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Common Stock
Statement [Line Items]
Balance Beginning	$ 10,462	$ 6,302
Balance Beginning (in Shares)	10,461,898	6,302,050
Issuance of common stock and warrants in equity offering, net	$ 449
Issuance of common stock and warrants in equity offering, net (in Shares)	449,438
Issuance of common stock upon public offering, net of issuance costs		$ 2,500
Issuance of common stock upon public offering, net of issuance costs (in Shares)		2,500,000
Issuance of common stock in settlement of convertible notes and accrued interest		$ 1,511
Issuance of common stock in settlement of convertible notes and accrued interest (in Shares)		1,511,276
Placement of common stock		$ 31
Placement of common stock (in Shares)		30,864
Warrants issued with convertible notes
Shares issued for services	$ 11	$ 90
Shares issued for services (in Shares)	11,264	90,000
Shares issued for reverse stock split		$ 1
Shares issued for reverse stock split (in Shares)		1,211
Issuance of common stock under equity incentive plan	$ 27	$ 27
Issuance of common stock under equity incentive plan (in Shares)	26,789	26,497
Stock-based compensation
Net loss
Balance Ending	$ 10,949	$ 10,462
Balance Ending (in Shares)	10,949,389	10,461,898
Additional Paid-In Capital
Statement [Line Items]
Balance Beginning	$ 43,406,099	$ 14,665,559
Issuance of common stock and warrants in equity offering, net	7,371,898
Issuance of common stock upon public offering, net of issuance costs		13,657,500
Issuance of common stock in settlement of convertible notes and accrued interest		6,506,254
Placement of common stock		249,969
Warrants issued with convertible notes		3,700,632
Shares issued for services	21,716	594,310
Shares issued for reverse stock split		(1)
Issuance of common stock under equity incentive plan	86,021	172,091
Stock-based compensation	2,638,000	3,859,785
Net loss
Balance Ending	53,523,734	43,406,099
Accumulated Deficit
Statement [Line Items]
Balance Beginning	(34,579,771)	(15,947,010)
Issuance of common stock and warrants in equity offering, net
Issuance of common stock upon public offering, net of issuance costs
Issuance of common stock in settlement of convertible notes and accrued interest
Placement of common stock
Warrants issued with convertible notes
Shares issued for services
Shares issued for reverse stock split
Issuance of common stock under equity incentive plan
Stock-based compensation
Net loss	(13,878,936)	(18,632,761)
Balance Ending	(48,458,707)	(34,579,771)
Balance Beginning	8,836,790	(1,275,149)
Issuance of common stock and warrants in equity offering, net	7,372,347
Issuance of common stock upon public offering, net of issuance costs		13,660,000
Issuance of common stock in settlement of convertible notes and accrued interest		6,507,765
Placement of common stock		250,000
Warrants issued with convertible notes		3,700,632
Shares issued for services	21,727	594,400
Shares issued for reverse stock split
Issuance of common stock under equity incentive plan	86,048	172,118
Stock-based compensation	2,638,000	3,859,785
Net loss	(13,878,936)	(18,632,761)
Balance Ending	$ 5,075,976	$ 8,836,790

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flows from operating activities
Net loss	$ (13,878,936)	$ (18,632,761)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on PPP note forgiveness		(368,780)
Loss on debt extinguishment		1,321,450
Stock-based compensation expense	2,724,048	4,031,902
Depreciation and amortization	152,399	117,490
Accrued interest		666,338
Shares issued for services	202,669	395,950
Amortization of debt issuance costs		1,833,618
Other		274
Changes in assets and liabilities:
Prepaid expenses and other assets	(14,384)	65,652
Lease right-of-use assets	203,047	79,431
Accounts payable and accrued expenses	(200,762)	354,948
Change in lease liabilities	(199,725)	(125,040)
Net cash used in operating activities	(11,011,644)	(10,259,528)
Cash flows from investing activities
Purchases of property and equipment	(1,637,751)	(54,764)
Net cash used in investing activities	(1,637,751)	(54,764)
Cash flows from financing activities
Proceeds from private placement, net		250,000
Proceeds from issuance of convertible notes, net		4,137,199
Proceeds from issuance of promissory note		2,100,000
Repayment of promissory note		(2,100,000)
Proceeds from issuance of common stock and warrants, net	7,372,347	13,535,000
Net cash provided by financing activities	7,372,347	17,922,199
Net increase (decrease) in cash and cash equivalents	(5,277,048)	7,607,907
Cash and cash equivalents, at beginning of year	9,076,372	1,468,465
Cash and cash equivalents, at end of year	3,799,324	9,076,372
Noncash investing and financing activities:
Right of use asset obtained in exchange for lease liabilities	1,560,101
Fair value of detachable warrants issued with convertible notes		3,700,632
Conversion of convertible notes and accrued interest into common stock		7,253,876
Cash paid for:
Income taxes	1,600	1,600
Interest paid		$ 262,000

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc. The Company is a development stage medical device company focused on the design, development and eventual commercialization of an innovative insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product candidate, or MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product candidate seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In February 2022, the Company completed a public offering of its equity securities, and its common stock was approved to list on the Nasdaq Capital Market under the symbol “MODD” and began trading there on February 10, 2022. Liquidity and Going Concern The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company’s expected operating losses and cash burn raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. These consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. In May 2022 and May 2023, the Company completed offerings of its common stock and warrants. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2023 refers to the fiscal year ending March 31, 2023). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. Reverse Stock Split On November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company’s shares of common stock. Such amendment and ratio were previously approved by a majority of the Company’s stockholders and the board of directors. As a result of the reverse stock split, which was effective November 29, 2021, every three shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company’s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse stock split. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates. Reportable Segment The Company operates in one business segment and uses one measurement of profitability for its business. Research and Development The Company expenses research and development expenditures as incurred. General and Administrative General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at a high credit quality financial institution within the United States, which is insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure. Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. Recent Economic Disruptions The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in- place” and created significant disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and “shelter-in-place” orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company’s operational and financial performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread are uncertain, out of our control, and cannot be predicted. The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively impacted the global economy. Since mid-2022, the U.S. Federal Reserve has addressed elevated inflation by increasing interest rates, as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to our business. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Property and Equipment Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service. Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value. Debt Modifications and Extinguishments When the Company modifies or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 470-50, Debt— Modifications and Extinguishments, Leases The Company’s right-of-use assets consist of leased assets recognized in accordance with FASB ASC No. 842, Leases Stock-Based Compensation The Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and projected stock option exercise behaviors. Per-Share Amounts Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants. The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive: March 31, 2023 2022 Options to purchase common stock 2,481,090 1,650,705 Common stock warrants 7,565,588 4,779,072 Total 10,046,678 6,429,777 Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. Income Taxes The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance. The Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, Income Taxes The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2023 and 2022, the Company’s comprehensive loss was the same as its net loss. Recently Issued Accounting Pronouncement In June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments—Credit Losses

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	12 Months Ended
	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
CONSOLIDATED BALANCE SHEET DETAIL	NOTE 2 – CONSOLIDATED BALANCE SHEET DETAIL March 31, 2023 2022 Property and equipment, net: Machinery and equipment $ 820,058 $ 230,947 Computer equipment and software 65,890 52,114 Construction-in-process 1,002,726 — Leasehold improvements 25,298 139,197 Office equipment 63,393 63,298 1,977,365 485,556 Less: accumulated depreciation and amortization (256,054 ) (249,597 ) Total property and equipment, net $ 1,721,311 $ 235,959 March 31, 2023 2022 Accrued Expenses Accrued wages and bonus $ 267,316 $ 457,891 Other 71,382 67,000 $ 338,698 $ 524,891

Leases

Leases	12 Months Ended
	Mar. 31, 2023
Leases [Abstract]
LEASES	NOTE 3 – LEASES W. Bernardo Drive, San Diego, CA The 39-month lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400 annual rent increases of approximately 3%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. A discount rate of 11%, which approximated the Company’s incremental borrowing rate, was used to measure the lease asset and liability. The Company obtained a right-of-use asset of $270,950 in exchange for its obligations under the operating lease. The landlord also provided a lease incentive of approximately $139,000, which was paid to the Company in June 2020, for the Company to make improvements to the leased space. In addition, the Company paid a $100,000 security deposit. Thornmint Road, San Diego, CA The 48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and other certain operating costs. A discount rate of 8%, which approximated the Company’s incremental borrowing rate, was used to measure the lease asset and liability. The Company obtained a right-of-use asset of $1,560,101 in exchange for its obligations under the operating lease. Future minimum payments under the facility operating leases, as of March 31, 2023, are listed in the table below. Fiscal year ending March 31, 2024 $ 462,008 2025 452,275 2026 470,366 2027 404,951 Total future lease payments 1,789,600 Less: Imputed interest (244,409 ) Present value of lease liabilities $ 1,545,191 Cash paid for amounts included in the measurement of lease liabilities was $230,028 and $153,432 for the years ended March 31, 2023 and 2022, respectively. Rent expense was $237,425 and $107,820 for the years ended March 31, 2023 and 2022, respectively.

PPP Note

PPP Note	12 Months Ended
	Mar. 31, 2023
PPP Note [Abstract]
PPP NOTE	NOTE 4 – PPP NOTE In April 2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established under the U.S. government’s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program Note with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds. In May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470, and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated statements of operations.

Convertible Promissory Notes

Convertible Promissory Notes	12 Months Ended
	Mar. 31, 2023
Convertible Promissory Notes [Abstract]
CONVERTIBLE PROMISSORY NOTES	NOTE 5 – CONVERTIBLE PROMISSORY NOTES From February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of Notes and 2021 Warrants (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $1,321,450 and interest expense of $70,647 for unamortized debt issuance costs as of April 30, 2021. During the three months ended June 30, 2021, pursuant to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold to investors $4,250,000 aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of its common stock (the 2021 Warrants). The Notes were unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date and accrued interest at a rate of 12% per annum, payable on maturity. If the Company completed an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as defined in the Notes), each Note holder would be required to convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25. In connection with the issuance of the Notes, the Company issued the 2021 Warrants to purchase in the aggregate 767,796 shares of its common stock at an initial exercise price of $24.00 per share. The fair value of the 2021 Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount and amortized to interest expense, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of 88.98%, risk-free interest rate of 0.86%, a term of 5.75 years and a dividend yield of zero. Upon the closing of a public offering in February 2022, which was a Qualified Capital Raise, in accordance with their terms, the Notes converted into 1,511,276 shares of common stock and the holders of the Notes received an additional 1,511,276 common stock purchase warrants with an exercise price of $6.60 per share. In addition, as a result of the February 2022 equity offering, the exercise price of the 767,796 outstanding 2021 Warrants was reduced to $6.00 per share.

Promissory Note

Promissory Note	12 Months Ended
	Mar. 31, 2023
Promissory Note [Abstract]
PROMISSORY NOTE	NOTE 6 – PROMISSORY NOTE In October 2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (Explorer) that provided the Company with a $3,000,000 revolving credit facility with all amounts being drawn down by the Company thereunder being due and payable, subject to acceleration in the event of a default, on March 15, 2022 (the Maturity Date). Interest at the rate of 12% was payable on each drawn down without regard to the draw down date or the date when interest is paid. During fiscal 2022, the Company made draws on the Bridge Note of $2,100,000 and incurred interest charges of $252,000. In February 2022, subsequent to the completion of the 2022 Offering (see Note 7), the Bridge Note and accrued interest was paid in full.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2023
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 7 – STOCKHOLDERS’ EQUITY February 2022 Public Offering On February 9, 2022, the Company entered into an underwriting agreement with Oppenheimer & Co. Inc., who acted as the representative of the several underwriters (the Underwriters), in a firm commitment underwritten public offering (the 2022 Offering) pursuant to which, on February 14, 2022, the Company sold to the Underwriters an aggregate of 2,500,000 shares of the Company’s common stock and 2,500,000 warrants (the Offering Warrants and, collectively with the shares of common stock, the Units), each to purchase one share of common stock. The price to the public in the 2022 Offering was $6.00 per Unit, before underwriting discounts and commissions. The common stock and the Offering Warrants comprising the Units were immediately separable upon issuance and were issued separately. The Offering Warrants were exercisable immediately, have an exercise price of $6.60 per share and expire on February 14, 2027. The gross proceeds from the 2022 Offering were $15,000,000, before deducting approximately $1,465,000 of underwriting discounts and commissions and other offering expenses. Placements of Common Stock and Warrants On May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant to which the Company sold, in a registered direct offering, which closed on May 5, 2022, an aggregate of 449,438 shares (the Shares) of the Company’s common stock, par value $0.001 per share, at a purchase price per Share of $4.45 and pre-funded warrants (the Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44. The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. In a concurrent private placement under the Purchase Agreement, the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants will be exercisable beginning on the six-month anniversary of the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise Date. In October 2021, the Company sold 30,864 shares of common stock to two officers, its i) chief executive officer and ii) the chairman of the Company’s board of directors (the Board), president, chief financial officer and treasurer, at a purchase price of Issuances of Common Stock and Warrants During the years ended March 31, 2023 and 2022, the Company issued 11,264 and 90,000 shares of common stock to service providers, respectively, with fair values of approximately $21,727 and $594,400, respectively. Warrants As of March 31, 2023, the Company had the following warrants outstanding: Number of Exercise Type Shares Prices Expiration Dates Common stock 1,348,314 $ 0.01 — Common stock 767,796 $ 6.00 January - February 2027 Common stock 4,011,276 $ 6.60 February 2027 Common stock 1,438,202 $ 6.60 November 2027 Total 7,565,588 As of March 31, 2022, the Company had the following warrants outstanding: Number of Exercise Type Shares Prices Expiration Dates Common stock 767,796 $ 6.00 January - February 2027 Common stock 4,011,276 $ 6.60 February 2027 Total 4,779,072

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]
STOCK-BASED COMPENSATION	NOTE 8 – STOCK-BASED COMPENSATION Amended 2017 Equity Incentive Plan In October 2017, the Company’s Board approved the 2017 Equity Incentive Plan (the Plan) with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan by 333,334 and 1,333,334 shares, respectively. In January 2023, the Company’s stockholders approved an increase in the number of shares reserved for issuance under the Plan by an additional 2,000,000 shares. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board. Stock-Based Compensation Expense The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant date fair value. The unamortized compensation cost, as of March 31, 2023, was $3,268,600 related to stock options and is expected to be recognized as expense over a weighted-average period of approximately two years. During the year ended March 31, 2023, the Company granted options to purchase 1,006,074 shares of its common stock to employees, directors and consultants. The options had 10-year terms and 123,407 options vested immediately when granted. The weighted-average grant date fair value of stock options granted during the years ended March 31, 2023 and 2022 was $2.85 and $10.28, respectively. The following assumptions were used in the fair-value method calculations: Year Ended March 31, 2023 2022 Risk-free interest rates 2.82% - 4.06% 0.8% - 2.42% Volatility 83% - 223% 89% - 370% Expected life (years) 5.0 - 5.7 5.0 - 6.2 Dividend yield — — The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options. The expected volatility is based on the historical volatility of the Company’s stock price. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. A summary of stock option activity under the Plan is presented below: Options Outstanding Shares Available for Grant Number of Weighted Balance at March 31, 2021 136,082 1,197,252 $ 5.25 Additional shares authorized under the Plan 1,333,334 — — Options granted (827,427 ) 827,427 10.39 Share awards (26,497 ) — — Options cancelled and returned to the Plan 373,974 (373,974 ) 10.73 Balance at March 31, 2022 989,466 1,650,705 6.58 Additional shares authorized under the Plan 2,000,000 — — Options granted (1,006,074 ) 1,006,074 3.15 Share awards (26,789 ) — — Options cancelled and returned to the Plan 175,689 (175,689 ) 6.48 Balance at March 31, 2023 2,132,292 2,481,090 $ 5.19 There were no stock options exercised during the years ended March 31, 2023 and 2022. The Company issued 26,789 shares to its non-employee directors under the Company’s outside director compensation plan and approximately $86,048 was recorded as stock-based compensation expense for these share awards during the year ended March 31, 2023. The following table summarizes the range of outstanding and exercisable options as of March 31, 2023: Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $ 1.44 – $3.95 982,358 7.78 $ 2.05 531,797 $ 2.04 $ 319 $ 4.18 - $7.51 969,600 8.05 5.46 572,600 6.32 — $ 8.61 - $17.70 529,132 8.25 10.53 379,634 10.49 — 2,481,090 7.99 $ 5.19 1,484,031 $ 5.87 $ 319 The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option at March 31, 2023.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2023
Income Taxes [Abstract]
INCOME TAXES	NOTE 9 – INCOME TAXES The income tax provision consisted of the following: Year Ended March 31, 2023 2022 Current portion: Federal $ — $ — State 1,600 1,600 1,600 1,600 Deferred portion: Federal (2,933,000 ) (4,109,000 ) State (1,467,000 ) (1,300,000 ) (4,400,000 ) (5,409,000 ) Change in valuation allowance 4,400,000 5,409,000 Provision for income taxes $ 1,600 $ 1,600 At March 31, 2023, the Company had net operating loss carryforwards (NOLs) of approximately $29,500,000 for federal income tax purposes and $36,600,000 for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times from 2037 through 2043, except federal NOLs from fiscal 2018 and later, which will never expire. The Company also had federal research and development tax credit carryforwards of approximately $1,300,000, which will begin expiring at various times from 2038 through 2042, and state research and development credits of approximately $400,000, which do not have an expiration date. A reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows: Year Ended March 31, 2023 2022 Federal statutory rate (21 )% (21 )% State tax rate, net of federal benefit (6 )% (7 )% Research and development tax credits (6 )% (2 )% Change in valuation allowance 29 % 30 % Other 4 % — % Effective income tax rate — % — % The losses before income tax provision for the years ended March 31, 2023 and 2022 were solely attributable to US operations. Significant components of the Company’s deferred tax assets and liabilities were: March 31, 2023 2022 Net operating loss carryforwards $ 8,742,000 $ 7,731,000 Stock-based compensation expense 2,587,000 1,824,000 Property and equipment 105,000 80,000 Reserves, accruals & other 1,841,000 (104,000 ) Research and development tax credits 1,658,000 988,000 Total deferred tax assets 14,933,000 10,519,000 Section 179 assets (111,000 ) (97,000 ) Total deferred tax liabilities (111,000 ) (97,000 ) Less: valuation allowance (14,822,000 ) (10,422,000 ) Deferred tax assets, net $ — $ — Based on the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March 31, 2023 and 2022, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets at March 31, 2023 and 2022. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements at March 31, 2023 and 2022. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.

Royalty Agreement

Royalty Agreement	12 Months Ended
	Mar. 31, 2023
Royalty Agreement [Abstract]
ROYALTY AGREEMENT	NOTE 10 – ROYALTY AGREEMENT In July 2017, the Company entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder (the Founder). Pursuant to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for future royalty payments on the Company’s product. The Company is obligated to make royalty payments under the agreement to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement, reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference between total royalty payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the preceding quarter, will be made by the Company to the Founder within 30 days after the end of each calendar quarter.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11 – COMMITMENTS AND CONTINGENCIES Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company’s consolidated financial statements for the years ended March 31, 2023 and 2022 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements. Purchase Obligations The Company’s primary purchase obligations include purchase orders for machinery and equipment. At March 31, 2023, the Company had outstanding purchase orders for machinery and equipment and related expenditures of approximately $833,000.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 12 – RELATED PARTY TRANSACTIONS Manchester Management Company, LLC (MMC), as the general partner of Explorer, combined with the holdings of its affiliates, JEB Partners LP, James Besser and Morgan Frank, owned approximately 25% of the Company’s outstanding shares of common stock as of March 31, 2023. Mr. Besser is the Company’s chief executive officer and a managing member of MMC. Mr. Frank is one of our directors and serves as the portfolio manager of Explorer and as a managing member of MMC. The daughter of the Founder is an employee of the Company. During the years ended March 31, 2023 and 2022, the Company paid her $201,275 and $169,589, respectively, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718, of stock options granted to her. In May 2021, a member of the Board purchased $200,000 aggregate principal amount of Notes (the Director Note). On February 14, 2022, in connection with the Offering, the Director Note and $18,805 of accrued interest thereon were converted into 45,586 shares of common stock and 45,586 Offering Warrants. In February 2021, Explorer, which is represented by Mr. Frank, and the Founder (the Related Party Holders) purchased $1,000,000 and $100,000,

Subsequent Event

Subsequent Event	12 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 13 – SUBSEQUENT EVENT On May 15, 2023, the Company entered into an underwriting agreement (the Underwriting Agreement) with Newbridge Securities Corporation (the Underwriter), with respect to the issuance and sale in a firm commitment underwritten offering (the 2023 Offering) by the Company of units of its securities for aggregate gross proceeds of approximately $9,400,000, before deducting underwriting discounts and commissions and other offering expenses. The Company sold 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common stock. The securities were sold as a unit, with each unit consisting of two shares of common stock of the Company and one warrant (the 2023 Warrant) to purchase one share of common stock, at a public offering price of $2.13 per unit. The 2023 Warrants were immediately separable and exercisable, had a per share exercise price of $1.22 and expire five years from the date of issuance. The 2023 Offering closed on May 18, 2023. Pursuant to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,322,534 shares of common stock and an additional 661,267 of the 2023 Warrants to cover over-allotments, if any. On May 25, 2023, the Underwriter exercised in full this option and purchased the additional securities for aggregate gross proceeds to the Company of approximately $1,400,000, before deducting underwriting discounts and commissions and other offering expenses. The Underwriter was paid a cash fee of 7.0% of the aggregate gross proceeds of the Offering and reimbursed certain out-of-pocket expenses of $125,000. Pursuant to the Underwriting Agreement, the Company issued to the Underwriter a five-year warrant to purchase 709,760 shares of common stock a per share exercise price of $1.22. The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related “lock-up” agreements, the Company, each director and executive officer of the Company, and certain stockholders have agreed with the Underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of 90 days after May 17, 2023.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Liquidity and Going Concern	Liquidity and Going Concern The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. The Company’s expected operating losses and cash burn raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. These consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. In May 2022 and May 2023, the Company completed offerings of its common stock and warrants. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.
Basis of Presentation	Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2023 refers to the fiscal year ending March 31, 2023). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.
Reverse Stock Split	Reverse Stock Split On November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company’s shares of common stock. Such amendment and ratio were previously approved by a majority of the Company’s stockholders and the board of directors. As a result of the reverse stock split, which was effective November 29, 2021, every three shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company’s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse stock split.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.
Reportable Segment	Reportable Segment The Company operates in one business segment and uses one measurement of profitability for its business.
Research and Development	Research and Development The Company expenses research and development expenditures as incurred.
General and Administrative	General and Administrative General and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees, and office and other administrative expenses.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at a high credit quality financial institution within the United States, which is insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. Recent Economic Disruptions The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in- place” and created significant disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and “shelter-in-place” orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company’s operational and financial performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread are uncertain, out of our control, and cannot be predicted. The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively impacted the global economy. Since mid-2022, the U.S. Federal Reserve has addressed elevated inflation by increasing interest rates, as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to our business.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.
Property and Equipment	Property and Equipment Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.
Debt Modifications and Extinguishments	Debt Modifications and Extinguishments When the Company modifies or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 470-50, Debt— Modifications and Extinguishments,
Leases	Leases The Company’s right-of-use assets consist of leased assets recognized in accordance with FASB ASC No. 842, Leases
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and projected stock option exercise behaviors.
Per-Share Amounts	Per-Share Amounts Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants. The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive: March 31, 2023 2022 Options to purchase common stock 2,481,090 1,650,705 Common stock warrants 7,565,588 4,779,072 Total 10,046,678 6,429,777
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.
Income Taxes	Income Taxes The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance. The Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, Income Taxes The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.
Comprehensive Loss	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2023 and 2022, the Company’s comprehensive loss was the same as its net loss.
Recently Issued Accounting Pronouncement	Recently Issued Accounting Pronouncement In June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments—Credit Losses

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of the company and summary of significant accounting policies	March 31, 2023 2022 Options to purchase common stock 2,481,090 1,650,705 Common stock warrants 7,565,588 4,779,072 Total 10,046,678 6,429,777

Consolidated Balance Sheet De_2

Consolidated Balance Sheet Detail (Tables)	12 Months Ended
	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Schedule of property and equipment, net	March 31, 2023 2022 Property and equipment, net: Machinery and equipment $ 820,058 $ 230,947 Computer equipment and software 65,890 52,114 Construction-in-process 1,002,726 — Leasehold improvements 25,298 139,197 Office equipment 63,393 63,298 1,977,365 485,556 Less: accumulated depreciation and amortization (256,054 ) (249,597 ) Total property and equipment, net $ 1,721,311 $ 235,959
Schedule of accrued expenses	March 31, 2023 2022 Accrued Expenses Accrued wages and bonus $ 267,316 $ 457,891 Other 71,382 67,000 $ 338,698 $ 524,891

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of future minimum payments under the facility operating leases	Fiscal year ending March 31, 2024 $ 462,008 2025 452,275 2026 470,366 2027 404,951 Total future lease payments 1,789,600 Less: Imputed interest (244,409 ) Present value of lease liabilities $ 1,545,191

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Mar. 31, 2023
Stockholders' Equity [Abstract]
Schedule of warrants outstanding	Number of Exercise Type Shares Prices Expiration Dates Common stock 1,348,314 $ 0.01 — Common stock 767,796 $ 6.00 January - February 2027 Common stock 4,011,276 $ 6.60 February 2027 Common stock 1,438,202 $ 6.60 November 2027 Total 7,565,588 Number of Exercise Type Shares Prices Expiration Dates Common stock 767,796 $ 6.00 January - February 2027 Common stock 4,011,276 $ 6.60 February 2027 Total 4,779,072

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Schedule of fair-value assumptions of options	Year Ended March 31, 2023 2022 Risk-free interest rates 2.82% - 4.06% 0.8% - 2.42% Volatility 83% - 223% 89% - 370% Expected life (years) 5.0 - 5.7 5.0 - 6.2 Dividend yield — —
Schedule of stock option activity	Options Outstanding Shares Available for Grant Number of Weighted Balance at March 31, 2021 136,082 1,197,252 $ 5.25 Additional shares authorized under the Plan 1,333,334 — — Options granted (827,427 ) 827,427 10.39 Share awards (26,497 ) — — Options cancelled and returned to the Plan 373,974 (373,974 ) 10.73 Balance at March 31, 2022 989,466 1,650,705 6.58 Additional shares authorized under the Plan 2,000,000 — — Options granted (1,006,074 ) 1,006,074 3.15 Share awards (26,789 ) — — Options cancelled and returned to the Plan 175,689 (175,689 ) 6.48 Balance at March 31, 2023 2,132,292 2,481,090 $ 5.19
Schedule of outstanding and exercisable option, range	Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $ 1.44 – $3.95 982,358 7.78 $ 2.05 531,797 $ 2.04 $ 319 $ 4.18 - $7.51 969,600 8.05 5.46 572,600 6.32 — $ 8.61 - $17.70 529,132 8.25 10.53 379,634 10.49 — 2,481,090 7.99 $ 5.19 1,484,031 $ 5.87 $ 319

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of income tax provision	Year Ended March 31, 2023 2022 Current portion: Federal $ — $ — State 1,600 1,600 1,600 1,600 Deferred portion: Federal (2,933,000 ) (4,109,000 ) State (1,467,000 ) (1,300,000 ) (4,400,000 ) (5,409,000 ) Change in valuation allowance 4,400,000 5,409,000 Provision for income taxes $ 1,600 $ 1,600
Schedule of reconciliation of income taxes provided at the federal statutory rate	Year Ended March 31, 2023 2022 Federal statutory rate (21 )% (21 )% State tax rate, net of federal benefit (6 )% (7 )% Research and development tax credits (6 )% (2 )% Change in valuation allowance 29 % 30 % Other 4 % — % Effective income tax rate — % — %
Schedule of significant components of the company’s deferred tax assets and liabilities	March 31, 2023 2022 Net operating loss carryforwards $ 8,742,000 $ 7,731,000 Stock-based compensation expense 2,587,000 1,824,000 Property and equipment 105,000 80,000 Reserves, accruals & other 1,841,000 (104,000 ) Research and development tax credits 1,658,000 988,000 Total deferred tax assets 14,933,000 10,519,000 Section 179 assets (111,000 ) (97,000 ) Total deferred tax liabilities (111,000 ) (97,000 ) Less: valuation allowance (14,822,000 ) (10,422,000 ) Deferred tax assets, net $ — $ —

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Details)	12 Months Ended
	Mar. 31, 2023 USD ($)
The Company and Summary of Significant Accounting Policies (Details) [Line Items]
Federal deposit insurance corporation (in Dollars)	$ 250,000
Tax percentage	50%
Minimum [Member]
The Company and Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	3 years
Maximum [Member]
The Company and Summary of Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	5 years

The Company and Summary of Si_4

The Company and Summary of Significant Accounting Policies (Details) - Schedule of the company and summary of significant accounting policies - shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule of the company and summary of significant accounting policies [Abstract]
Options to purchase common stock	2,481,090	1,650,705
Common stock warrants	7,565,588	4,779,072
Total	10,046,678	6,429,777

Consolidated Balance Sheet De_3

Consolidated Balance Sheet Detail (Details) - Schedule of property and equipment, net - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Property and equipment, net:
Property and equipment, gross	$ 1,977,365	$ 485,556
Less: accumulated depreciation and amortization	(256,054)	(249,597)
Total property and equipment, net	1,721,311	235,959
Machinery and equipment [Member]
Property and equipment, net:
Property and equipment, gross	820,058	230,947
Computer equipment and software [Member]
Property and equipment, net:
Property and equipment, gross	65,890	52,114
Construction-in-process [Member]
Property and equipment, net:
Property and equipment, gross	1,002,726
Leasehold improvements [Member]
Property and equipment, net:
Property and equipment, gross	25,298	139,197
Office equipment [Member]
Property and equipment, net:
Property and equipment, gross	$ 63,393	$ 63,298

Consolidated Balance Sheet De_4

Consolidated Balance Sheet Detail (Details) - Schedule of accrued expenses - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Accrued Expenses
Accrued wages and bonus	$ 267,316	$ 457,891
Other	71,382	67,000
Total accrued expenses	$ 338,698	$ 524,891

Leases (Details)

Leases (Details) - USD ($)		12 Months Ended
	Apr. 01, 2020	Mar. 31, 2023	Mar. 31, 2022	Feb. 01, 2023
Leases [Abstract]
Lessee, operating lease, term of contract	39 months			48 months
Monthly rent	$ 12,400	$ 36,000
Percentage of annual rent	3%	4%
Percentage of borrowing interest rate	11%	8%
Obtained a right-of-use asset of exchange obligations operating leas		$ 1,560,101	$ 270,950
Lease incentive payable			139,000
Security deposit			100,000
Cash paid for lease liabilities		230,028	153,432
Rent expense		$ 237,425	$ 107,820

Leases (Details) - Schedule of

Leases (Details) - Schedule of future minimum payments under the facility operating leases	Mar. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 462,008
2025	452,275
2026	470,366
2027	404,951
Total future lease payments	1,789,600
Less: Imputed interest	(244,409)
Present value of lease liabilities	$ 1,545,191

PPP Note (Details)

PPP Note (Details)	Apr. 30, 2020 USD ($)
PPP Note [Abstract]
Unsecured loan	$ 368,780
Fixed rate of interest	1%

Convertible Promissory Notes (D

Convertible Promissory Notes (Details) - USD ($)			3 Months Ended	12 Months Ended
	Feb. 28, 2022	Apr. 30, 2021	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Convertible Promissory Notes (Details) [Line Items]
Convertible Notes Payable		$ 2,310,000
Aggregate principal amount		2,360,550
Gain (loss) on extinguishment of debt		1,321,450			$ (1,321,450)
Unamortized debt issuance costs		70,647			$ 1,833,618
Maturity date			12 months
Accrued interest at a rate			12%
Stock converted to other securities			$ 12,000,000
Principal plus accrued interest description				(i) the sum of all outstanding principal plus accrued interest on a Note, multiplied by (ii) 1.25.
Aggregate common stock (in Shares)						767,796
Exercise price per share (in Dollars per share)	$ 6.6					$ 24
Fair value warrants						$ 3,700,632
Unamortized debt issuance costs						1,321,450
Dividend yield
Converted shares (in Shares)	1,511,276
Additional common stock purchase (in Shares)	1,511,276
Equity offering, exercise price (in Shares)	767,796
Reduced warrants exercise price (in Dollars per share)	$ 6
Warrant [Member]
Convertible Promissory Notes (Details) [Line Items]
Gain (loss) on extinguishment of debt						$ 2,379,182
Volatility rate						88.98%
Risk-free interest rate						0.86%
Share-based compensation expected term						5 years 9 months
Dividend yield						0%
Revocation Agreement [Member]
Convertible Promissory Notes (Details) [Line Items]
Convertible Notes Payable		$ 2,310,000
Convertible Notes Payable [Member]
Convertible Promissory Notes (Details) [Line Items]
Convertible Notes Payable			$ 4,250,000

Promissory Note (Details)

Promissory Note (Details) - USD ($)		12 Months Ended
	Oct. 31, 2021	Mar. 31, 2022
Promissory Note [Abstract]
Revolving credit facility amount	$ 3,000,000
Maturity date	Mar. 15, 2022
Interest rate	12%
Drawn amount		$ 2,100,000
Interest charges incurred		$ 252,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)		1 Months Ended		12 Months Ended
	May 05, 2022	Feb. 14, 2022	Oct. 31, 2021	Mar. 31, 2023	Mar. 31, 2022
Stockholders' Equity [Abstract]
Underwriters an aggregate shares		2,500,000
Common stock warrants shares		2,500,000
Offering per unit				$ 6
Warrants exercise price per share				$ 6.6
Maturity date				Feb. 14, 2027
Offering cost				$ 15,000,000
Underwriting discounts and commissions				$ 1,465,000
Aggregate shares	449,438
Common stock, par value	$ 0.001			$ 0.001	$ 0.001
Purchase price per share	$ 4.45
Aggregate purchase shares	1,348,314
Warrant price per share	$ 4.44
Exercise price per share	$ 0.01
Purchase an aggregate shares	1,438,202
Common stock exercise price	$ 6.6
Sold shares of common stock		23,429	30,864
Purchase price per share			$ 8.1
Gross proceeds			$ 250,000
Shares issued				11,264	90,000
Fair values amount				$ 21,727	$ 594,400

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of warrants outstanding - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Class of Warrant or Right [Line Items]
Number of Shares	7,565,588	4,779,072
Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of Shares	1,348,314
Exercise Prices (in Dollars per share)	$ 0.01
Expiration Dates
Common stock one [Member]
Class of Warrant or Right [Line Items]
Number of Shares	767,796
Exercise Prices (in Dollars per share)	$ 6
Expiration Dates	January - February 2027
Common stock two [Member]
Class of Warrant or Right [Line Items]
Number of Shares	4,011,276
Exercise Prices (in Dollars per share)	$ 6.6
Expiration Dates	February 2027
Common stock three [Member]
Class of Warrant or Right [Line Items]
Number of Shares	1,438,202
Exercise Prices (in Dollars per share)	$ 6.6
Expiration Dates	November 2027
Common stock four [Member]
Class of Warrant or Right [Line Items]
Number of Shares		767,796
Exercise Prices (in Dollars per share)		$ 6
Expiration Dates		January - February 2027
Common stock five [Member]
Class of Warrant or Right [Line Items]
Number of Shares		4,011,276
Exercise Prices (in Dollars per share)		$ 6.6
Expiration Dates		February 2027

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2017	Mar. 31, 2023	Jan. 31, 2023	Mar. 31, 2022	Aug. 31, 2021	Jan. 31, 2020
Stock-Based Compensation (Details) [Line Items]
Shares approved under equity incentive plan	1,000,000
Common stock, capital shares reserved for future issuance			2,000,000		1,333,334	333,334
Unamortized compensation cost (in Dollars)		$ 3,268,600
weighted-average period years		2 years
Options terms year		10 years
Options vested shares		123,407
Weighted-average grant date fair value of stock options granted price (in Dollars per share)		$ 2.85		$ 10.28
Stock based compensation (in Dollars)		$ 86,048
Director [Member]
Stock-Based Compensation (Details) [Line Items]
Granted options shares		1,006,074
Non-employee Directors [Member]
Stock-Based Compensation (Details) [Line Items]
Shares issued		26,789

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Line Items]
Dividend yield
Minimum [Member]
Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Line Items]
Risk-free interest rates	2.82%	0.80%
Volatility	83%	89%
Expected life (years)	5 years	5 years
Maximum [Member]
Stock-Based Compensation (Details) - Schedule of fair-value assumptions of options [Line Items]
Risk-free interest rates	4.06%	2.42%
Volatility	223%	370%
Expected life (years)	5 years 8 months 12 days	6 years 2 months 12 days

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of stock option activity - Equity Option [Member] - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-Based Compensation (Details) - Schedule of stock option activity [Line Items]
Shares Available for Grant, Beginning balance	989,466	136,082
Number of Shares, Beginning balance	1,650,705	1,197,252
Weighted Average Exercise Price, Beginning balance (in Dollars per share)	$ 6.58	$ 5.25
Additional shares authorized under the Plan, Shares Available for Grant	2,000,000	1,333,334
Additional shares authorized under the Plan, Number of Shares
Additional shares authorized under the Plan, Weighted Average Exercise Price (in Dollars per share)
Options granted, Shares Available for Grant	(1,006,074)	(827,427)
Options granted, Number of Shares	1,006,074	827,427
Options granted, Weighted Average Exercise Price (in Dollars per share)	$ 3.15	$ 10.39
Share awards, Shares Available for Grant	(26,789)	(26,497)
Share awards, Number of Shares
Share awards, Weighted Average Exercise Price (in Dollars per share)
Options cancelled and returned to the Plan, Shares Available for Grant	175,689	373,974
Options cancelled and returned to the Plan, Number of Shares	(175,689)	(373,974)
Options cancelled and returned to the Plan, Weighted Average Exercise Price (in Dollars per share)	$ 6.48	$ 10.73
Shares Available for Grant, Ending balance	2,132,292	989,466
Number of Shares, Ending balance	2,481,090	1,650,705
Weighted Average Exercise Price, Ending balance (in Dollars per share)	$ 5.19	$ 6.58

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range	12 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]
Number Outstanding, | shares	2,481,090
Weighted Average Remaining Contractual Life (in Years)	7 years 11 months 26 days
Weighted Average Exercise Price, Options Outstanding | $ / shares	$ 5.19
Number Exercisable | shares	1,484,031
Aggregate Intrinsic value | $	$ 319
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 5.87
$1.44 – $3.95 [Member]
Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]
Number Outstanding, | shares	982,358
Weighted Average Remaining Contractual Life (in Years)	7 years 9 months 10 days
Weighted Average Exercise Price, Options Outstanding | $ / shares	$ 2.05
Number Exercisable | shares	531,797
Aggregate Intrinsic value | $	$ 319
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 2.04
$4.18 - $7.51 [Member]
Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]
Number Outstanding, | shares	969,600
Weighted Average Remaining Contractual Life (in Years)	8 years 18 days
Weighted Average Exercise Price, Options Outstanding | $ / shares	$ 5.46
Number Exercisable | shares	572,600
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 6.32
$8.61 - $17.70 [Member]
Stock-Based Compensation (Details) - Schedule of outstanding and exercisable option, range [Line Items]
Number Outstanding, | shares	529,132
Weighted Average Remaining Contractual Life (in Years)	8 years 3 months
Weighted Average Exercise Price, Options Outstanding | $ / shares	$ 10.53
Number Exercisable | shares	379,634
Weighted Average Exercise Price, Options Exercisable | $ / shares	$ 10.49

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Mar. 31, 2023 USD ($)
Income Taxes [Abstract]
Net operating loss carryforwards federal income tax	$ 29,500,000
Net operating loss carryforwards state income tax	36,600,000
Federal research and development tax credit	1,300,000
State research and development credits	$ 400,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of income tax provision - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Current portion:
Federal
State	1,600	1,600
Current income tax provision	1,600	1,600
Deferred portion:
Federal	(2,933,000)	(4,109,000)
State	(1,467,000)	(1,300,000)
Deferred income tax provision	(4,400,000)	(5,409,000)
Change in valuation allowance	4,400,000	5,409,000
Provision for income taxes	$ 1,600	$ 1,600

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of reconciliation of income taxes provided at the federal statutory rate	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule of reconciliation of income taxes provided at the federal statutory rate [Abstract]
Federal statutory rate	(21.00%)	(21.00%)
State tax rate, net of federal benefit	(6.00%)	(7.00%)
Research and development tax credits	(6.00%)	(2.00%)
Change in valuation allowance	29%	30%
Other	4%
Effective income tax rate

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of significant components of the company’s deferred tax assets and liabilities - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Schedule of significant components of the company’s deferred tax assets and liabilities [Abstract]
Net operating loss carryforwards	$ 8,742,000	$ 7,731,000
Stock-based compensation expense	2,587,000	1,824,000
Property and equipment	105,000	80,000
Reserves, accruals & other	1,841,000	(104,000)
Research and development tax credits	1,658,000	988,000
Total deferred tax assets	14,933,000	10,519,000
Section 179 assets	(111,000)	(97,000)
Total deferred tax liabilities	(111,000)	(97,000)
Less: valuation allowance	(14,822,000)	(10,422,000)
Deferred tax assets, net

Royalty Agreement (Details)

Royalty Agreement (Details)	Jul. 31, 2017 USD ($) $ / shares
Royalty Agreement (Details) [Line Items]
Gross sale price percentage	5%
Royalty payments actually paid	$ 10,000,000
Total royalty payments	$ 10,000,000
Founder [Member]
Royalty Agreement (Details) [Line Items]
Sale of royalty product (in Dollars per share) | $ / shares	$ 0.75

Commitments and Contingencies (

Commitments and Contingencies (Details)	12 Months Ended
	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase of machinery and equipment outstanding	$ 833,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended		12 Months Ended
	Feb. 14, 2022	Feb. 28, 2021	Mar. 31, 2023	Mar. 31, 2022	Oct. 31, 2021	May 31, 2021
Related Party Transactions (Details) [Line Items]
Company paid amount			$ 201,275	$ 169,589
Interest payable	$ 9,788
Converted shares (in Shares)	45,586
Aggregate principal amount	$ 102,663
Shares of common stock (in Shares)	23,429				30,864
Offering warrants (in Shares)	23,429
Founder [Member]
Related Party Transactions (Details) [Line Items]
Aggregate principal amount		$ 100,000
Warrants [Member]
Related Party Transactions (Details) [Line Items]
Converted shares (in Shares)	45,586
Mr. Besser [Member]
Related Party Transactions (Details) [Line Items]
Ownership percentage			25%
Board [Member]
Related Party Transactions (Details) [Line Items]
Notes payable						$ 200,000
Interest payable	$ 18,805
Mr. Frank [Member]
Related Party Transactions (Details) [Line Items]
Aggregate principal amount		$ 1,000,000
Related Party Holders [Member]
Related Party Transactions (Details) [Line Items]
Interest payable	97,881
Aggregate principal amount	$ 1,026,630
Shares of common stock (in Shares)	234,274
Offering warrants (in Shares)	234,274

Subsequent Event (Details)

Subsequent Event (Details) - USD ($)		1 Months Ended	12 Months Ended
	May 15, 2023	May 25, 2023	Mar. 31, 2023
Subsequent Event (Details) [Line Items]
Underwriter cash fee payment percentage			7%
Reimbursement expenses (in Dollars)			$ 125,000
Common Stock [Member]
Subsequent Event (Details) [Line Items]
Additional shares purchased			1,322,534
Warrant [Member]
Subsequent Event (Details) [Line Items]
Number of warrants			709,760
Exercise price per share (in Dollars per share)			$ 1.22
Additional shares purchased			661,267
Subsequent Event [Member]
Subsequent Event (Details) [Line Items]
Aggregate gross proceeds (in Dollars)	$ 9,400,000
Number of shares sold	8,816,900
Number of warrants	4,408,450
Offering price per unit (in Dollars per share)	$ 2.13
Exercise price per share (in Dollars per share)	$ 1.22
Warrants expiration	5 years
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event (Details) [Line Items]
Number of shares sold	2
Number of warrants	1
Subsequent Event [Member] | Warrant [Member]
Subsequent Event (Details) [Line Items]
Number of shares sold	1
Forecast [Member]
Subsequent Event (Details) [Line Items]
Aggregate gross proceeds (in Dollars)		$ 1,400,000